EClinicalMedicine (Oct 2023)
Time to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community’s view
- Lan Yao,
- Hiam Chemaitelly,
- Emanuel Goldman,
- Esayas Kebede Gudina,
- Asma Khalil,
- Rahaman Ahmed,
- Ayorinde Babatunde James,
- Anna Roca,
- Mosoka Papa Fallah,
- Andrew Macnab,
- William C. Cho,
- John Eikelboom,
- Farah Naz Qamar,
- Peter Kremsner,
- Miquel Oliu-Barton,
- Ivan Sisa,
- Birkneh Tilahun Tadesse,
- Florian Marks,
- Lishi Wang,
- Jerome H. Kim,
- Xia Meng,
- Yongjun Wang,
- Alyce D. Fly,
- Cong-Yi Wang,
- Sara W. Day,
- Scott C. Howard,
- J. Carolyn Graff,
- Marcello Maida,
- Kunal Ray,
- Carlos Franco-Paredes,
- Tapfumanei Mashe,
- Ngashi Ngongo,
- Jean Kaseya,
- Nicaise Ndembi,
- Yu Hu,
- Maria Elena Bottazzi,
- Peter J. Hotez,
- Ken J. Ishii,
- Gang Wang,
- Dianjun Sun,
- Lotfi Aleya,
- Weikuan Gu
Affiliations
- Lan Yao
- Department of Nutrition and Health Science, College of Health, Ball State University, Muncie, IN 47306, USA; Department of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Centre, Memphis, TN 38163, USA
- Hiam Chemaitelly
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA
- Emanuel Goldman
- Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ 07103, USA
- Esayas Kebede Gudina
- Department of Internal Medicine, Jimma University Institute of Health, Jimma, Ethiopia
- Asma Khalil
- Fetal Medicine Unit, St George’s Hospital, St George’s University of London, London, UK; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George’s University of London, London, UK
- Rahaman Ahmed
- Cell Biology and Genetics Department, University of Lagos, Lagos 101017, Nigeria; Centre for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Lagos 100001, Nigeria
- Ayorinde Babatunde James
- Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria
- Anna Roca
- Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Fajara 273, The Gambia
- Mosoka Papa Fallah
- Refuge Place International, Monrovia, Liberia; Centre for Emerging Infectious Diseases Policy and Research, Boston University, Boston, MA, USA; Africa Centre for Disease Control, Addis Ababa, Ethiopia
- Andrew Macnab
- The Stellenbosch Institute for Advanced Study (STIAS), Wallenberg Research Centre at Stellenbosch University, South Africa
- William C. Cho
- Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China
- John Eikelboom
- Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada
- Farah Naz Qamar
- Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Karachi, Sindh 74800, Pakistan
- Peter Kremsner
- Institut für Tropenmedizin, Universität Tübingen, Germany; Centre de Recherches Medicales de Lambarene, Gabon
- Miquel Oliu-Barton
- Université Paris Dauphine – PSL, Pl. du Maréchal de Lattre de Tassigny, Paris 75016, France; Bruegel, Rue de la Charité 33, Brussels 1210, Belgium
- Ivan Sisa
- College of Health Sciences, Universidad San Francisco de Quito, Quito 170901, Ecuador
- Birkneh Tilahun Tadesse
- International Vaccine Institute, Seoul, Republic of Korea
- Florian Marks
- International Vaccine Institute, Seoul, Republic of Korea
- Lishi Wang
- Department of Basic Medicine, Inner Mongolia Medical University, Jinshan Development Zone, Huhhot, China
- Jerome H. Kim
- International Vaccine Institute, Seoul, Republic of Korea; Seoul National University, College of Natural Sciences, Seoul, Republic of Korea
- Xia Meng
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
- Yongjun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
- Alyce D. Fly
- Department of Nutrition and Health Science, College of Health, Ball State University, Muncie, IN 47306, USA
- Cong-Yi Wang
- NHC Key Laboratory of Respiratory Diseases, Department of Respiratory and Critical Care Medicine, The Centre for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
- Sara W. Day
- College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38105, USA
- Scott C. Howard
- College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38105, USA
- J. Carolyn Graff
- College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38105, USA
- Marcello Maida
- Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta 93100, Italy
- Kunal Ray
- School of Biological Science, Ramkrishna Mission Vivekananda Education & Research Institute, Narendrapur 700103, West Bengal, India
- Carlos Franco-Paredes
- Hospital Infantil de Mexico, Federico Gomez, Mexico; Department of Microbiology, Immunology, and Pathology, Colorado State University, USA
- Tapfumanei Mashe
- One Health Office, Ministry of Health and Child Care, Harare, Zimbabwe; World Health Organization, Harare, Zimbabwe
- Ngashi Ngongo
- Institute of Human Virology, Abuja, Nigeria
- Jean Kaseya
- Institute of Human Virology, Abuja, Nigeria
- Nicaise Ndembi
- Institute of Human Virology, Abuja, Nigeria
- Yu Hu
- Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China; Hubei Clinical and Research Centre of Thrombosis and Hemostasis, Wuhan, China
- Maria Elena Bottazzi
- Department of Pediatrics, Texas Children's Hospital Centre for Vaccine Development, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA
- Peter J. Hotez
- Department of Pediatrics, Texas Children's Hospital Centre for Vaccine Development, Baylor College of Medicine, Houston, TX, USA; National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA
- Ken J. Ishii
- Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Centre, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Centre for Vaccine Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Gang Wang
- Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
- Dianjun Sun
- Centre for Endemic Disease Control, Chinese Centre for Disease Control and Prevention, Harbin Medical University; Key Laboratory of Etiologic Epidemiology, Education Bureau of Heilongjiang Province & Ministry of Health 23618104, 157 Baojian Road, Harbin, Heilongjiang 150081, China; Corresponding author. 157 Baojian Road, Harbin, Heilongjiang 150081, China.
- Lotfi Aleya
- Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, Besançon Cedex F-25030, France; Corresponding author. Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, Besançon Cedex F-25030, France.
- Weikuan Gu
- Department of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Centre, Memphis, TN 38163, USA; Research Service, Memphis VA Medical Centre, 1030 Jefferson Avenue, Memphis, TN 38104, USA; Corresponding author. 956 Court Avenue, Memphis, TN 38163, USA.
- Journal volume & issue
-
Vol. 64
p. 102222
Abstract
Summary: In counteracting highly infectious and disruptive respiratory diseases such as COVID-19, vaccination remains the primary and safest way to prevent disease, reduce the severity of illness, and save lives. Unfortunately, vaccination is often not the first intervention deployed for a new pandemic, as it takes time to develop and test vaccines, and confirmation of safety requires a period of observation after vaccination to detect potential late-onset vaccine-associated adverse events. In the meantime, nonpharmacologic public health interventions such as mask-wearing and social distancing can provide some degree of protection. As climate change, with its environmental impacts on pathogen evolution and international mobility continue to rise, highly infectious respiratory diseases will likely emerge more frequently and their impact is expected to be substantial. How quickly a safe and efficacious vaccine can be deployed against rising infectious respiratory diseases may be the most important challenge that humanity will face in the near future. While some organizations are engaged in addressing the World Health Organization's ''blueprint for priority diseases'', the lack of worldwide preparedness, and the uncertainty around universal vaccine availability, remain major concerns. We therefore propose the establishment of an international candidate vaccine pool repository for potential respiratory diseases, supported by multiple stakeholders and countries that contribute facilities, technologies, and other medical and financial resources. The types and categories of candidate vaccines can be determined based on information from previous pandemics and epidemics. Each participant country or region can focus on developing one or a few vaccine types or categories, together covering most if not all possible potential infectious diseases. The safety of these vaccines can be tested using animal models. Information for effective candidates that can be potentially applied to humans will then be shared across all participants. When a new pandemic arises, these pre-selected and tested vaccines can be quickly tested in RCTs for human populations.
